QIAGEN N.V. Annual Report 2001

QIAGEN N.V. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
Years Ended December 31,
2001
2000
1999
Net sales
Cost of sales
Gross profit
Operating Expenses:
$ 263,770,000
79,673,000
184,097,000
$ 216,802,000
65,436,000
151,366,000
$ 158,155,000
45,836,000
112,319,000
Research and development
Sales and marketing
General and administrative
Acquisition costs
In-process research and development
Total operating expenses
Income from operations
Other Income (Expense):
26,769,000
64,830,000
36,022,000
3,000,000
–
130,621,000
53,476,000
23,372,000
54,931,000
31,177,000
5,353,000
–
114,833,000
36,533,000
17,813,000
39,948,000
26,110,000
–
5,100,000
88,971,000
23,348,000
31
Interest income
Interest expense
Research and development grants
Gain (loss) on foreign currency transactions, net
Loss from equity method investees
Other miscellaneous income, net
Total other income
Income before provision for income
taxes and minority interest
Provision for income taxes
Minority interest
Net income
Basic net income per common share
Diluted net income per common share
Shares used in computing basic net income
per common share
Shares used in computing diluted net income
per common share
1,795,000
(991,000)
1,526,000
31,000
(1,373,000)
1,859,000
2,847,000
56,323,000
21,896,000
8,000
$ 34,419,000
$ 0.24
$ 0.24
142,962,000
145,055,000
3,032,000
(1,622,000)
1,212,000
(231,000)
(870,000)
1,070,000
2,591,000
39,124,000
18,085,000
36,000
$ 21,003,000
$ 0.15
$ 0.14
142,040,000
145,071,000
1,576,000
(1,306,000)
1,116,000
420,000
(637,000)
471,000
1,640,000
24,988,000
10,950,000
149,000
$ 13,889,000
$ 0.10
$ 0.10
140,317,000
142,186,000
The accompanying notes are an integral part of these consolidated financial statements.